A new study on Nature's website has followed people with inflammatory bowel disease (IBD) who switched their vedolizumab treatment from a hospital drip to injections they can give themselves at home. The researchers looked at how well the medicine kept working, and how safe it was, over 48 weeks. We have not yet been able to read the full paper, so we can't report its findings. But the question it asks matters to many people with Crohn's disease and ulcerative colitis (UC) in the UK.
About vedolizumab
Vedolizumab (brand name Entyvio) is a biologic medicine. This is a type of treatment made from proteins that targets one specific part of the immune system. Vedolizumab stops certain white blood cells from moving out of the blood into the lining of the gut, where they drive inflammation. It is used for moderate to severe Crohn's disease and UC.
It was first available only as an intravenous (IV) infusion, a drip into a vein, usually given in a hospital day unit. A subcutaneous (SC) version, injected just under the skin with a prefilled pen or syringe, is now available too. People normally have at least two IV doses first, then move on to injections, which are usually given every two weeks.
What the study looked at
From its title, this is a "real-world" study. That means researchers followed people being treated in ordinary clinics, rather than running a controlled trial in which patients are put into groups at random. The people in it had switched from IV to SC vedolizumab, and the researchers measured how effective and how safe the treatment was over 48 weeks, almost a year.
At this stage we don't know who carried out the study, in which country, how many patients took part, whether they had Crohn's disease, UC or both, or exactly what was measured. We also don't know who paid for it. We will update this article once we have checked the full paper.
What earlier studies have shown
This is not the first study of its kind. Real-world studies from several countries, including Spain, Germany, Canada and Japan, have looked at the same switch. Broadly, they reported that most people who were well on drips stayed in remission (having few or no symptoms and little inflammation) after moving to injections, and that no new safety concerns came to light. Patient satisfaction was generally high.
The main downside reported was injection-site reactions, such as redness, swelling or soreness where the needle goes in.
Real-world studies are useful because they show what happens in everyday care. But they have limits. Without a comparison group it is harder to be sure what caused any changes, and the people offered a switch are often those whose disease is already well controlled.
What it means for you
If you have vedolizumab drips, injecting at home could mean fewer trips to hospital and less time off work or school. Some people find that a real gain. Others prefer to stay on the drip: it is given less often, and some people don't like injecting themselves or value regular contact with the infusion team.
Subcutaneous vedolizumab is licensed in the UK for adults with moderate to severe Crohn's disease or UC. The National Institute for Health and Care Excellence (NICE) recommended vedolizumab for both conditions in 2015, and a number of NHS hospitals now offer home injections to people whose disease is stable. Whether and when a switch is offered can differ between hospitals.
What happens next
The new study adds to a growing body of real-world evidence on this switch. Once we have seen the full paper, we will report what it found, including how many people stayed well and how many had side effects.
If you would like to move from drips to injections, or you are unsure about a switch your team has suggested, talk it through with your IBD nurse or consultant. Don't stop or change your vedolizumab without their advice, and contact them promptly if your symptoms return after any change. You can read more about how vedolizumab works and what to do in a flare-up.
Ref: Authors not yet confirmed. Switching from IV to SC vedolizumab in IBD: real-world effectiveness and safety over 48 weeks. Nature Portfolio (journal, volume and date to be confirmed), 2026. https://news.google.com/rss/articles/CBMiX0FVX3lxTE1xeWpPZU5iMmhKT1hQMVdpOHRyb3Zib2tRUXgtaFFEUlZwSHg0c3BraVN1OU5TRlU4NFRyNkc0OVhvaEloX21uNGpadHBrOG5uaFlBRXNSV04ySzBQOXNz?oc=5